Participation of B cell in immunotherapy of cancer
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155169 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Nikhil Chandnani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India. Hauptthemen laut MEDLINE: Tertiary Lymphoid Structures, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Science and Engineering Research Board, Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Even though their effector roles extend beyond conventional humoral immunity, B and plasma cells may exhibit antitumor effects through antibody-dependent cell cytotoxicity (ADCC) and activation of the complement cascade. Depending on whether they are positioned in immature or mature compartments termed tertiary lymphoid structures (TLS), which include T cells, B cells are believed to play numerous functions in modulating the immune system's capacity to destroy cancer cells. These formations represent a process of lymphoid neogenesis that takes place in peripheral tissues in response to prolonged exposure to inflammatory signals. Activated in the germinal centres of tertiary lymphoid structures, B cells may directly present tumor-associated antigens to T cells, make antibodies that enhance antigen presentation to T cells, or kill tumour cells, resulting in a favourable therapeutic effect. Immune complexes may also enhance inflammation, angiogenesis, and immunosuppression via the activation of macrophages and complement, resulting in detrimental effects. The functional variety of B-cell subsets includes professional antigen-presenting cells, regulatory cells, memory populations, and plasma cells that produce antibodies. Importantly, antibodies may independently generate innate immune responses and the cancer immunity cycle. B cells and B-cell-mediated antibody responses constitute the largely underestimated second arm of the adaptive immune system and unquestionably need more consideration in cancer. This article reviews the known roles of B lymphocytes in the tumour microenvironment, their contribution to anticancer activity of immunotherapies, and their significance in overall survival of cancer patients. In addition to producing antibodies, B cells regulate the immune system and serve as effective antigen-presenting cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India.
- Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India. Electronic address: koustavsarkar@gmail.com.
Förderung
- Science and Engineering Research Board
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Chandnani, N., Gupta, I., Mandal, A., & Sarkar, K. (2024). Participation of B cell in immunotherapy of cancer. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155169
Vancouver
Chandnani N, Gupta I, Mandal A, Sarkar K. Participation of B cell in immunotherapy of cancer. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155169
BibTeX
@article{Chandnani2024,
author = {Chandnani, Nikhil and Gupta, Ishika and Mandal, Ayush and Sarkar, Koustav},
title = {Participation of B cell in immunotherapy of cancer},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155169}
}
EUVIMED